Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials
Open Access
- 1 July 1996
- journal article
- Published by Elsevier in The Lancet
- Vol. 348 (9021) , 150-154
- https://doi.org/10.1016/s0140-6736(96)01501-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Life Expectancy in Four U.S. Racial/Ethnic PopulationsEpidemiology, 1995
- Helicobacter pylori in Peptic Ulcer DiseaseJAMA, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- The time trend and age—period—cohort effects on incidence of adenocarcinoma of the stomach in connecticut from 1955–1989Cancer, 1993
- HELICOBACTER PYLORI AND GASTRIC CANCERGastroenterology Clinics of North America, 1993
- Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese populationGastroenterology, 1992
- Helicobacter pyloriInfection and the Risk of Gastric CarcinomaNew England Journal of Medicine, 1991
- Epidemiology of Helicobacter pylori in an asymptomatic population in the United StatesGastroenterology, 1991
- Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.BMJ, 1991
- Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic PersonsNew England Journal of Medicine, 1989